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Abstract 
Cutaneous apocrine gland carcinoma, a subtype of sweat gland carcinoma, is a very rare 
malignancy, and only few cases have been reported in the literature. Many of these 
carcinomas are indolent and slowly developing, but some are rapidly progressive. The 
treatment of choice is wide local excision with clear margins, with or without lymph node 
dissection. We report a case of a 67-year-old man who came to our hospital with an 
ulcerated nodule in the right axilla measuring 1 × 0.8 cm. Histological evaluation showed 
features of an apocrine gland carcinoma arising in an area of high apocrine gland density. 
 
Introduction 
Primary cutaneous apocrine gland carcinoma, a subtype of sweat gland carcinoma, is 
an extremely rare malignant neoplasm [1–3]. Most of these neoplasms involve the 
axilla, but lesions can also occur elsewhere on the skin. Most often, they are indolent 
and slowly developing, but some are rapidly progressive and extremely aggressive [1, 
4–6]. In fact, some patients have died from widespread metastases. The treatment of 
choice is wide local excision with clear margins, with or without lymph node dissection 
[1, 3, 5, 7]. 
Case Report 
A 67-year-old man presented to our hospital with an ulcerated nodule in the right axilla measuring 
1 × 0.8 cm. The nodule had been present for more than 3 years, but only grew in size over the past 6 
months. Bilateral breast examination, skin examination and complete lymph node survey were 
unremarkable. Ultrasound examination and a mammogram revealed no significant lesions in either Case Rep Oncol 2011;4:597–601 
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breast, consistent with the physical examination. There was no family history of malignancy. The 
nodule was excised and the specimen submitted for histopathological examination. 
Microscopic examination revealed a well-to-moderately differentiated adenocarcinoma which 
contained ductal and glandular structures with obvious apocrine features. Some of the glandular 
lumens showed decapitation secretion. In addition, the cytoplasm of the tumour cells contained 
PAS-positive diastase-resistant granules without iron-staining granules. The tumour tissue invaded 
the papillary and reticular dermis and ulcerated the epidermis without extension to the subcutaneous 
tissue (fig. 1, fig. 2). Many apocrine glands were present near the carcinoma. The 
immunohistochemical study showed that the tumour cells were positive for Ker7, EMA and 
E-cadherin and negative for CEA, S100p and PSA. No oestrogen or progesterone receptors were 
detected, making the diagnosis of male breast cancer metastatic to the axilla unlikely (fig. 3, fig. 4). 
Based on the above characteristic morphologic and immunohistochemical findings, the diagnosis 
of primary apocrine carcinoma was made. Two years later, the patient showed no evidence of 
metastasis. 
Discussion 
Cutaneous apocrine gland carcinoma, a subtype of sweat gland carcinoma, is a very 
rare malignant neoplasm arising in areas of high apocrine sweat gland density. To date, 
only few cases (about 50 cases) have been reported in the literature [1]. The first 
report was published in 1944 [8]. 
These lesions occur primarily in the axilla, but can also occur elsewhere on the skin 
[1–3, 9]. The disease is diagnosed in the fifth to seventh decade of life. Apocrine 
adenocarcinoma usually develops de novo but has also been observed to arise in 
association with other benign tumours such as apocrine adenoma and apocrine 
hyperplasia [10, 11]. Most of the neoplasms are relatively indolent and slowly 
developing over months to years, but some are rapidly progressive and extremely 
aggressive. They mostly present as nodules or masses 2–3 cm in size, without any 
additional symptoms [1, 3, 5, 6]. One third of the patients have regional lymph node 
involvement at diagnosis. Also, some patients have died from metastases to the lungs, 
liver, bone, brain and kidney [1, 3, 5]. 
The histologic picture likes as an adenocarcinoma that may be well, moderate or 
poorly differentiated [1, 3, 9]. The adenocarcinoma contains ductal or glandular 
structures with apocrine features. The cytoplasm of the tumour cells contains PAS-
positive, diastase-resistant granules and often iron-positive granules [1, 7, 9, 12]. 
The differential diagnosis of apocrine gland carcinoma from metastatic mammary 
adenocarcinoma is not possible on morphological grounds, and immunohistochemistry, 
except for a few cases, does not allow distinction between them. Malignant sweat gland 
tumours are often positive for oestrogen and progesterone receptors, and these 
markers are therefore of limited usage in differential diagnosis [1, 3, 9]. Features that 
favour the diagnosis of a primary apocrine gland carcinoma are the presence of 
neoplastic glands high in the dermis, apocrine glands near the tumour and 
intracytoplasmic granules of iron [9]. The treatment of choice is wide local excision 
with clear margins, with or without regional lymph node dissection. Postoperative 
radiotherapy and chemotherapy in patients with moderately or poorly differentiated 
tumours have been used as adjunctive treatments but have shown little benefit on 
mortality [1, 3, 5, 13, 14]. There is a high incidence of local recurrence (28% in one Case Rep Oncol 2011;4:597–601 
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report), and prophylactic nodal dissection does not reduce the incidence of local 
recurrence [15]. 
Primary apocrine carcinoma of sweat glands is a very rare tumour, and there are no 
guidelines for the treatment of recurrent or metastatic disease. Therefore, patients with 
metastatic progression have a very poor prognosis. 
 
 
 
 
 
 
Fig. 1. Apocrine carcinoma. HE. ×40. 
 
 
 
Fig. 2. Apocrine carcinoma. HE. ×200. 
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Fig. 3. Apocrine carcinoma. KER 7. ×40. 
 
 
 
Fig. 4. Apocrine carcinoma. E-cadherin. ×200. 
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